RESUMEN
OBJECTIVE:To investigate the effects of valsartan on related indexes of elderly patients with hypertension with paroxysmal atrial fibrillation.METHODS:A total of 128 patients with hypertension with paroxysmal atrial fibrillation were randomly divided into observation group and control group,with 64 cases in each group.Control group was given Amlodipine tablets 5-10 mg/d,once a day+Hydrochlorothiazide tablets 12.5 mg/d,once a day,orally in the morning.Observation group was additionally given Valsartan capsule 80-160 mg/d orally,once a day,in the morning.Both groups were treated for 12 weeks.The levels of Hs-CRP,IL-6 and blood pressure,LVEF,LAD,maximum P wave duration (Pmax),P wave dispersion (Pd) before and after treatment,the occurrence of ADR were observed and compared between 2 groups.RESULTS:Before treatment,there was no statistical significance in above indexes (P＞0.05).After treatment,Hs-CRP,IL-6 levels and LAD of 2 groups were significantly lower than before,and Hs-CRP,IL-6 levels in the observation group was significantly lower than the control group while LAD was higher than the control groups;LVEF was significantly higher than before,but the observation group was significantly lower than the control group,with statistical significance (P＜0.05).After treatment,SBP and DBP of 2 groups were significantly lower than before (P＜0.05),but there was no statistical significance between 2 groups (P＞0.05).Pmax and Pd in the observation group were significantly lower than before,and lower than the control group at the same time(P＜0.05),while there were no significantly of Pmax and Pd in the control group before and after treatment(P＞0.05).No obvious ADR was found in 2 groups during treatment.CONCLUSIONS:For elderly patients with hypertension with paroxysmal atrial fibrillation,valsartan shows good hypotensive effect and effectively improves serum inflammatory factor levels and cardiac function related indexes.
RESUMEN
AIM: To established an HPLC/MS/MS method for the study of pharmcokinetics of PMEA-Na (the mono-sodium salts of 9-[2-(phosphonomethoxy) ethyl] adenine) in beagle dogs. METHODS: PMEA-Na and internal standard 9-(3-phosphony-methoxypropyl) adenine were isolated from plasma by protein precipitation with methanol, and then analyzed adopting multiple reaction monitoring (MRM) mode. Using Xterra MS column, the mobile phases consisted of methanol:water:formic acid (25:75:0.5) at a flow rate of 0.25 ml·min-1. Beagle dogs received the intravenous dosage of PMEA-Na at 1.0, 3.0 and 6.0 mg·kg-1. Pharmacokinetic parameters were obtained from concentration-time curves by non-linear least-squares regression using the program DAS. RESULTS: The linear calibration curve was obtained in the concentration range of 0.02 to 20 mg·L-1 (r=0.999), and the limit of quantitition was 20 μg·L-1. The within-day and internal-day precisions (RSD) were less than 6.5% and 10.8%, respectively. The accuracy was 97.1%～107.3%. After a single dose studies in dogs the AUC were 2.3±0.5, 8.2±1.3 and 18.5±1.3 mg·L-1·h; the t1/2 were 3.9±1.8, 8.4±1.5 and 8.9±0.6 h; the CL were 0.44±0.09, 0.35±0.05 and 0.31±0.03 ml·h-1·kg-1 at the dose level of 1.0, 3.0 and 6.0 mg·kg-1 respectively. CONCLUSION: The analytical method is sensitive and specific for investigation the pharmacokintics of PMEA-Na in beagle dogs.